[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fOU6kIfbZ0Dm8IKQhPTlUw6F04YzHeR5nmrhi6OhCBqU":8,"$fe3DkHXgoNJhzWVojM981AqOaBKgsZxI5qcdXzxscqvE":55,"$fP6YcLOMV95hZcw0P39lX6lEcGfOx2vWEQ9IqEfFmwBI":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48523,868812,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//zdvKwwpnMtYwusNReBVaFVjt4zA4Kj7D.png","蔡文","浙江大学医学院附属第二医院","肿瘤科","住院医师",28,0,"BRAF V600E突变相关药品使用全攻略：安全、规范、实用细节一文掌握","","https://cdn.yishi-tong.com/console/store-unknown/r2vS2pJPOqFTmJGJQHk9naTX--5ReIRp.png","\u003Cdiv class=\"braf_material_wrapper\">\n  \u003Ch1 id=\"material_title\" class=\"braf_material_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">BRAF V600E突变相关药品使用全攻略：安全、规范、实用细节一文掌握\u003C/h1>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg1\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、什么是BRAF V600E靶向用药？🌿\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>在药物治疗领域，BRAF V600E变异被视为肿瘤学用药分层的关键分子特征。针对这一突变，药师会优先考虑BRAF抑制剂、MEK抑制剂，以及EGFR抗体等联合用药方案。本文就为您全面梳理这类药品的分类、核心作用、服用方法以及用药风险防控，让安全和疗效兼得。\u003C/p>\n      \u003Cp>你将深入了解以下要点：\u003C/p>\n      \u003Cul>\n        \u003Cli>BRAF抑制剂的核心作用原理、剂型\u003C/li>\n        \u003Cli>MEK抑制剂联合应用机制\u003C/li>\n        \u003Cli>EGFR单抗用药细节\u003C/li>\n        \u003Cli>安全给药步骤及不良反应管理\u003C/li>\n        \u003Cli>常见用药误区与正确操作指南\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg2\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二、BRAF抑制剂用药细节全览💊\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>针对BRAF V600E突变，\u003Cspan class=\"braf_material_highlight\">维莫非尼(vemurafenib)\u003C/span>和\u003Cspan class=\"braf_material_highlight\">达拉非尼(dabrafenib)\u003C/span>两款口服制剂是最常用的BRAF抑制剂。不同制剂的部分细节，包括规格与服用方法，须格外留意：\u003C/p>\n      \n      \u003Cul>\n        \u003Cli>\u003Cstrong>成分简介：\u003C/strong>均为小分子激酶抑制剂，通过阻断BRAF蛋白异常活性，减缓细胞过度增殖。\u003C/li>\n        \u003Cli>\u003Cstrong>常见规格：\u003C/strong>\n          \u003Cul>\n            \u003Cli>维莫非尼常见为240mg片剂。\u003C/li>\n            \u003Cli>达拉非尼为50mg、75mg胶囊。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\u003Cstrong>推荐服用方式：\u003C/strong>\u003C/li>\n      \u003C/ul>\n      \u003Col>\n        \u003Cli>应整片/整粒吞服，使用温开水辅助，不可咬碎、压碎或嚼服。\u003C/li>\n        \u003Cli>\u003Cspan class=\"braf_material_highlight\">达拉非尼需空腹服用\u003C/span>：即在餐前至少1小时或餐后2小时服，避免影响药物吸收。\u003C/li>\n        \u003Cli>\u003Cspan class=\"braf_material_highlight\">维莫非尼可与或不与食物同服\u003C/span>：但需每日定时，避免剂量漏服。\u003C/li>\n        \u003Cli>建议每日两次给药，具体剂量基于医生开具的处方严格执行。\u003C/li>\n      \u003C/ol>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>💡 \u003Cstrong>正确做法：\u003C/strong> 确保隔12小时规律服用BRAF抑制剂，避免漏服或重复服药。漏服一顿如不到6小时，应立即补服，超时则跳过。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg3\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">三、MEK抑制剂联合应用要点🧬\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>MEK抑制剂如\u003Cspan class=\"braf_material_highlight\">曲美替尼(trametinib)\u003C/span>常与BRAF抑制剂联用，提升治疗率。此类药品的核心用药知识：\u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cstrong>成分与作用：\u003C/strong>抑制MAPK信号通路下游的MEK蛋白，有助联合封锁细胞异常增殖。\u003C/li>\n        \u003Cli>\u003Cstrong>常见规格：\u003C/strong>0.5mg、2mg片剂\u003C/li>\n        \u003Cli>\u003Cstrong>服用古法：\u003C/strong>\u003C/li>\n      \u003C/ul>\n      \u003Col>\n        \u003Cli>需空腹服用——餐前至少1小时或餐后2小时。\u003C/li>\n        \u003Cli>不可与BRAF抑制剂混合吞服，两者需分别按时给药。\u003C/li>\n        \u003Cli>避免用热饮或碳酸饮料送服，推荐常温水效果最佳。\u003C/li>\n      \u003C/ol>\n      \u003Cp>\u003Cstrong>正确做法：\u003C/strong> 将每日药物放入分装药盒，错开BRAF抑制剂与MEK抑制剂摄入时间，可有效减少漏服概率。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg4\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">四、EGFR单抗制剂用药须知🩺\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>EGFR靶向单抗（如\u003Cspan class=\"braf_material_highlight\">西妥昔单抗(cetuximab)\u003C/span>、\u003Cspan class=\"braf_material_highlight\">帕尼单抗(panitumumab)\u003C/span>）多为静脉注射制剂，用时注意：\u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cstrong>作用机制：\u003C/strong>靶向阻断EGFR信号通路，破坏异常信号输入，从而干预细胞生长。\u003C/li>\n        \u003Cli>\u003Cstrong>剂型特点：\u003C/strong>均需医院静脉输入，按照体表面积或体重，精确计量。\u003C/li>\n        \u003Cli>\u003Cstrong>正确的用药流程：\u003C/strong>\u003C/li>\n        \u003Col>\n          \u003Cli>注射剂需完全由训练有素的医务人员操作，严禁在家自行注射。\u003C/li>\n          \u003Cli>首次用药须随时监测即时反应，如有严重过敏症状，应立即停止给药并急诊处理。\u003C/li>\n          \u003Cli>明确药物溶解及稀释方案，不可使用未明确标注的溶媒。\u003C/li>\n        \u003C/ol>\n      \u003C/ul>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>⚠️ \u003Cstrong>特别提醒：\u003C/strong> EGFR单抗有输液相关反应风险，每次用药前后需观察生命体征，发生皮肤反应应及时报告医生。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg5\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">五、常用药物相互作用与联合给药建议🔗\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>某些药品合用时可产生有害相互作用。联合治疗常见的注意事项如下：\u003C/p>\n      \u003Cul>\n        \u003Cli>达拉非尼、MEK抑制剂与强效CYP3A4诱导剂（如利福平）合用时，药效有可能变弱。\u003C/li>\n        \u003Cli>达拉非尼与抗酸药、质子泵抑制剂合用会减少吸收效率。\u003C/li>\n        \u003Cli>西妥昔单抗合用其它静脉抗肿瘤药物时，引起皮肤类不良反应风险增加。\u003C/li>\n      \u003C/ul>\n      \u003Col>\n        \u003Cli>\u003Cspan class=\"braf_material_highlight\">正确做法：\u003C/span> \u003Cstrong>用药期间如添加新药，应主动向主治医生或药师报备，确认是否需调整时间。\u003C/strong>\u003C/li>\n        \u003Cli>避免自行购买感冒药、抗生素等新药与BRAF通路药物同服。\u003C/li>\n        \u003Cli>同一种口服药物，避免与葡萄柚汁、柑橘类饮品同饮。\u003C/li>\n      \u003C/ol>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>📣 \u003Cstrong>药师建议：\u003C/strong> 最靠谱的做法是将所用药品名称、用法及所有补充剂列出清单，由专业人员逐项分析。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg6\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">六、主要不良反应有哪些及应对方法🧑‍⚕️\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>服用BRAF、MEK抑制剂或EGFR单抗，可能遇到如下不良反应：\u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cstrong>皮肤反应：\u003C/strong>如皮疹、色素沉着等。临床数据显示，BRAF抑制剂相关皮肤不良反应发生率可达25%-40%（Long et al., 2014）。\u003C/li>\n        \u003Cli>\u003Cstrong>胃肠道反应：\u003C/strong>如食欲减退、腹泻，通常通过充足饮水、少量多餐缓解。\u003C/li>\n        \u003Cli>\u003Cstrong>发热、乏力：\u003C/strong>部分患者用药几天后可见，持续高热时应及时就医。\u003C/li>\n        \u003Cli>\u003Cstrong>心脏安全性：\u003C/strong>联合方案时QT间期延长等心律异常风险上升。\u003C/li>\n      \u003C/ul>\n      \u003Col>\n        \u003Cli>\u003Cspan class=\"braf_material_highlight\">正确做法：\u003C/span> 出现较轻反应先与主管药师沟通，用药反应明显加重或疑似严重时，建议尽快至医院评估。\u003C/li>\n        \u003Cli>出现发热、皮肤水泡、黄疸等异常变化不要擅自停药，立即联系主治医生。\u003C/li>\n        \u003Cli>为防止脱水和电解质失衡，保证每日饮水不少于1500ml。\u003C/li>\n      \u003C/ol>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>📊 \u003Cstrong>数据表明：\u003C/strong> 规范随访和早期管理能显著降低严重不良反应风险（Kopetz et al., 2019）。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg7\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">七、特殊人群用药调整💼\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>老年患者：\u003C/strong>药物代谢减慢，建议在初始剂量时特别核查肝肾功能，并按医嘱逐步调整。\u003C/li>\n        \u003Cli>\u003Cstrong>肝肾功能异常者：\u003C/strong>部分药物需要减量或调整给药间隔。\u003C/li>\n        \u003Cli>\u003Cstrong>孕妇、哺乳期妇女：\u003C/strong>使用BRAF抑制剂、MEK抑制剂或单抗类时应\u003Cstrong>严格避孕\u003C/strong>，如有生育需求务必咨询医生。\u003C/li>\n        \u003Cli>\u003Cstrong>儿童、青少年：\u003C/strong>目前多项药品未获全面儿童适应证，需权衡利弊并遵从医生指导。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>🙌 \u003Cstrong>正确做法：\u003C/strong>如家中有不清楚肝肾功能的老人开始用药，先做基础生化检查，根据化验单找专业药师定制方案。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n   \n  \u003Cdiv class=\"braf_material_section braf_material_bg8\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">八、药品储存、有效期与过量用药处理📦\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>储存条件：\u003C/strong>大部分BRAF、MEK抑制剂需存放于25℃以下干燥环境，\u003Cspan class=\"braf_material_highlight\">不得置于浴室、阳台\u003C/span>。\u003C/li>\n        \u003Cli>\u003Cstrong>EGFR单抗：\u003C/strong>需在专业药房或医疗场所冰箱储存，避免冻融波动。\u003C/li>\n        \u003Cli>\u003Cstrong>有效期：\u003C/strong>开封药瓶建议按照说明书限定时间服用，超过有效期务必丢弃勿用。\u003C/li>\n      \u003C/ul>\n      \u003Col>\n        \u003Cli>\u003Cspan class=\"braf_material_highlight\">正确做法：\u003C/span>使用带有日期标签的药盒，密封保存，并定期核验剩余药量与批号，有效期临近时写明提醒贴士。\u003C/li>\n        \u003Cli>\u003Cstrong>漏服处理：\u003C/strong>忘记服药6小时内可补服，超过则跳过该次。\u003C/li>\n        \u003Cli>\u003Cstrong>过量处理：\u003C/strong>如误服2倍及以上日剂量，应立即前往急诊，并说明具体所用的药品名称和剂量。\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_section braf_material_bg9\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">九、真实用药案例分享📝\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cul>\n        \u003Cli>一位55岁男性患者，规律服用BRAF抑制剂半年，联合化疗和EGFR单抗期间未出现严重不良反应，药盒分装帮助他避免漏服。\u003C/li>\n        \u003Cli>临床上，部分患者增加抗酸药后药效下降，经药师介入调整服药时间后，药物疗效得到改善。\u003C/li>\n        \u003Cli>用药期间出现皮肤红疹及时就医，个体化调整预后良好。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>✅ \u003Cstrong>经验教训：\u003C/strong>联合方案或自加新药时，应先查药物说明书，必要时让药师协助调整，防患风险于未然。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"braf_material_section braf_material_bg10\">\n    \u003Ch2 class=\"braf_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十、全面结语与核心提醒✔️\u003C/h2>\n    \u003Cdiv class=\"braf_material_content\">\n      \u003Cp>围绕BRAF V600E靶向用药，安全与规范必须双管齐下。服用前认准成分、剂型与餐食关系，严格遵从剂量。关注药物交互和个体状况调整，用药期间若出现不适，优先与专业药师联系。\u003C/p>\n      \u003Cul>\n        \u003Cli>每款药物均有独特服用规范及注意事项，是保障安全和效果的关键。\u003C/li>\n        \u003Cli>家庭用药管理便利化，不意味着放松警惕，随手做好用药记录与库存核查。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"braf_material_tips\">\n        \u003Cp>🔔 \u003Cstrong>请务必：\u003C/strong>避免擅自间断、加减药量，遇到药品相关的新疑惑，及时向专业人士请教。\u003C/p>\n        \u003Cp>希望这份详细用药指南，能为您和家人带来安全守护。愿每一片药、每一个提醒都成为健康的屏障。\u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"braf_material_reference\">\n    \u003Ch2 class=\"braf_material_subtitle_ref\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003Cul>\n      \u003Cli>Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., ... & Schadendorf, D. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. \u003Cem>New England Journal of Medicine, 371\u003C/em>(20), 1877-1888. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25265492/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., ... & Tabernero, J. (2019). Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. \u003Cem>New England Journal of Medicine, 381\u003C/em>(17), 1632-1643. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31566309/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., ... & Weber, J. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. \u003Cem>New England Journal of Medicine, 367\u003C/em>(18), 1694-1703. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23020132/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n/* BRAF用药材料独立样式（不影响全局） */\n.braf_material_wrapper {\n  max-width: 780px;\n  margin: 24px auto 48px auto;\n  padding: 32px 28px 40px 28px;\n  background: #f7fafc;\n  border-radius: 14px;\n  box-shadow: 0 8px 32px 0 rgba(60,60,60,0.05), 0 2px 8px 0 rgba(140,130,120,0.04);\n  font-family: \"PingFang SC\", \"Hiragino Sans GB\", Arial, sans-serif;\n  color: #2c3540;\n  font-size: 17px;\n  line-height: 2em;\n}\n.braf_material_title {\n  font-size: 2.1em;\n  letter-spacing: 1.2px;\n  color: #2d3c54;\n  margin-bottom: 24px;\n  font-weight: 700;\n  text-align: left;\n}\n.braf_material_section {\n  padding: 0 0 26px 0;\n  margin-bottom: 28px;\n  border-radius: 10px;\n  overflow: hidden;\n  box-shadow: 0 4px 12px 0 rgba(180,180,180,0.06);\n}\n\n.braf_material_subtitle {\n  font-size: 1.25em;\n  font-weight: 600;\n  margin: 0;\n  padding: 20px 18px 16px 18px;\n  border-bottom: 0;\n  color: #1361ba;\n  background: linear-gradient(90deg, rgba(212,241,255,0.6) 0%, rgba(246,250,255,0.40) 100%);\n  background-repeat: no-repeat;\n  background-position: center left;\n  letter-spacing: 0.4px;\n}\n.braf_material_content {\n  padding: 22px 24px 10px 28px;\n  background: rgba(250,252,255,0.67);\n  border-radius: 0 0 10px 10px;\n}\n.braf_material_content ul,\n.braf_material_content ol {\n  margin-top: 7px;\n  margin-bottom: 14px;\n  padding-left: 30px;\n}\n.braf_material_content ul li,\n.braf_material_content ol li {\n  margin-bottom: 7px;\n}\n.braf_material_content strong {\n  color: #194176;\n}\n.braf_material_highlight {\n  color: #e4781d;\n  font-weight: 600;\n  background: #fffbe9;\n  border-radius: 3.5px;\n  padding: 1px 4px;\n}\n.braf_material_tips {\n  margin: 11px 0 2px 0;\n  padding: 9px 15px 8px 21px;\n  background: linear-gradient(90deg, #e6f3f9 10%, #fff 100%);\n  border-left: 5px solid #a0d1ef;\n  border-radius: 6px;\n  color: #1e4f7a;\n  font-size: 1.01em;\n  line-height: 1.9em;\n  box-shadow: 0 2px 7px 0 rgba(150,150,150,0.05);\n}\n.braf_material_bg1 .braf_material_subtitle {\n  background: linear-gradient(90deg, #e0f3fc 0%, #f6fbfe 100%);\n}\n.braf_material_bg2 .braf_material_subtitle {\n  background: linear-gradient(90deg, #f8f1e1 0%, #f0f6fa 100%);\n}\n.braf_material_bg3 .braf_material_subtitle {\n  background: linear-gradient(90deg, #e9f7f0 0%, #fffbee 100%);\n}\n.braf_material_bg4 .braf_material_subtitle {\n  background: linear-gradient(90deg, #f4eff8 0%, #eaf1fd 100%);\n}\n.braf_material_bg5 .braf_material_subtitle {\n  background: linear-gradient(90deg, #e6f1f6 0%, #fff6ee 100%);\n}\n.braf_material_bg6 .braf_material_subtitle {\n  background: linear-gradient(90deg, #fcf2ef 0%, #edf8f0 100%);\n}\n.braf_material_bg7 .braf_material_subtitle {\n  background: linear-gradient(90deg, #e4f6f7 0%, #fff9f5 100%);\n}\n.braf_material_bg8 .braf_material_subtitle {\n  background: linear-gradient(90deg, #f7efe3 0%, #eef8fb 100%);\n}\n.braf_material_bg9 .braf_material_subtitle {\n  background: linear-gradient(90deg, #f7f3ee 0%, #f1fbfd 100%);\n}\n.braf_material_bg10 .braf_material_subtitle {\n  background: linear-gradient(90deg, #eafafc 0%, #f3f7fd 100%);\n}\n.braf_material_reference {\n  margin: 0 0 0 0;\n  padding: 24px 30px 26px 24px;\n  background: #f5f7fa;\n  border-radius: 10px;\n  font-size: 1em;\n  color: #3d4569;\n}\n.braf_material_subtitle_ref {\n  background: none;\n  color: #156fa9;\n  font-size: 1.09em;\n  padding: 0;\n  margin: 0 0 12px 0;\n  font-weight: 600;\n}\n.braf_material_reference ul, .braf_material_reference li {\n  margin-left: 0;\n  padding-left: 0;\n  list-style-position: inside;\n}\n.braf_material_reference em {\n  font-style: italic;\n  color: #535888;\n}\n@media (max-width: 660px) {\n  .braf_material_wrapper {\n    max-width: 96%;\n    padding:11px 7px 25px 7px;\n  }\n  .braf_material_content {\n    padding: 14px 7px 8px 12px;\n  }\n  .braf_material_reference {\n    padding: 17px 8px 16px 7px;\n    font-size: 0.98em;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"braf_material_wrapper\">\n  \u003Ch1 id=\"material_title\" class=\"braf_material_title\" style=\"col",550,"2025-07-12 09:30:20","BRAF抑制剂, MEK抑制剂, EGFR单抗, 癌症靶向药物, 用药指导, 不良反应管理, 药物相互作用, 肿瘤治疗","全面指南关于BRAF V600E靶向用药，含BRAF抑制剂、MEK抑制剂与EGFR抗体的使用细节，以及不良反应与药物相互作用，确保患者安全用药。","2025-07-13 23:14:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]